95673results about "Vector-based foreign material introduction" patented technology

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.

An inbred corn line, designated LH283BtMON810, is disclosed. The invention relates to the seeds of inbred corn line LH283BtMON810, to the plants of inbred corn line LH283BtMON810 and to methods for producing a corn plant, either inbred or hybrid, by crossing the inbred line LH283BtMON810 with itself or another corn line. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from the inbred LH283BtMON810.

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

The present invention relates to a promoter for regulating expression of foreign genes in transgenic organisms, which comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3 and functional fragments or derivatives thereof, wherein said promoter is adapted to be operationally located with respect to said foreign gene for expression of said gene.

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

A novel soybean cultivar, designated SN79525, is disclosed. The invention relates to the seeds of soybean cultivar SN79525, to the plants of soybean SN79525 and to methods for producing a soybean plant produced by crossing the cultivar SN79525 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar SN79525 with another soybean cultivar.

A novel soybean cultivar, designated S030160, is disclosed. The invention relates to the seeds of soybean cultivar S030160, to the plants of soybean S030160 and to methods for producing a soybean plant produced by crossing the cultivar S030160 with itself or another soybean variety. The invention further relates to transgenic soybean plants Produced by transforming a soybean of the cultivar S030160.

A soybean cultivar, designated 0037357, is disclosed. The invention relates to the seeds of soybean cultivar 0037357, to the plants of soybean 0037357 and to methods for producing a soybean plant produced by crossing the cultivar 0037357 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar 0037357 with another soybean cultivar.

A soybean cultivar, designated SE90346, is disclosed. The invention relates to the seeds of soybean cultivar SE90346, to the plants of soybean SE90346 and to methods for producing a soybean plant produced by crossing the cultivar SE90346 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar SE90346 with another soybean cultivar.

A novel soybean cultivar, designated S030010, is disclosed. The invention relates to the seeds of soybean cultivar S030010, to the plants of soybean S030010 and to methods for producing a soybean plant produced by crossing the cultivar S030010 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar S030010 with another soybean cultivar.

A soybean cultivar, designated 0509245, is disclosed. The invention relates to the seeds of soybean cultivar 0509245, to the plants of soybean 0509245 and to methods for producing a soybean plant produced by crossing the cultivar 0509245 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar 0509245 with another soybean cultivar.

The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

A novel soybean cultivar, designated 0491737, is disclosed. The invention relates to the seeds of soybean cultivar 0491737, to the plants of soybean 0491737 and to methods for producing a soybean plant produced by crossing the cultivar 0491737 with itself or another soybean variety. The invention further relates to transgenic soybean plants produced by transforming a soybean of the cultivar 0491737.

The invention provides variant heavy chain variable domains (VH) with increased folding stability. Libraries comprising a plurality of these polypeptides are also provided. In addition, compositions and methods of generating and using these polypeptides and libraries are provided.

The present invention provides human sequence antibodies against CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.

The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

The invention provides cropping systems for managing weeds in crop environments. The cropping systems comprise, in one embodiment, transgenic plants that display tolerance to an auxin-like herbicide such as dicamba. Method for minimizing the development of herbicide resistant weeds are also provided.

The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and / or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and / or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and / or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention also has important implications in the eradication of drug-resistant pathogens and drug-resistant diseased cells (such as cancer cells).

A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.

The invention provides for identification and use of certain chloroplast transit peptides for efficient processing and localization of dicamba monooxygenase (DMO) enzyme in transgenic plants. Methods for producing dicamba tolerant plants, methods for controlling weed growth, and methods for producing food, feed, and other products are also provided, as well as seed that confers tolerance to dicamba when it is applied pre- or post-emergence.

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

This invention is directed to the production of plants, plant tissues and seeds which are resistant to inhibition by an herbicide which normally inhibits the growth and development of those plants, plant tissues and plant seeds. In particular this invention is directed to altered acetohydroxyacid synthase enzymes which are resistant to inhibition by herbicides which normally inhibit the activity of the synthase before such alteration. This invention further relates to genes encoding such enzymes, and to processes for utilizing these novel genes and enzymes. Further products of the invention include plants, plant tissues and seeds which exhibit resistance to such herbicides resulting from expression of genes encoding herbicide resistant acetohydroxyacid synthase enzyme.

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

Plants, particularly cereal plants, which have improved ability to synthesise starch at elevated or lowered temperatures and / or to synthesise starch with an altered fine structure are produced by inserting into the genome of the plant (i) a gene(s) encoding a form of an enzyme of the starch or glycogen biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which display an activity which continues to increase over a temperature range over which the activity would normally be expected to decrease, and / or (ii) a gene(s) encoding sense and anti-sense constructs of enzymes of the starch biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which alters the natural ratios of expression of the said enzymes or inserts enzymes with special structural characteristics which alter the natural branching pattern in starch.

This disclosure provides several methods to generate nucleic acid mutations in vivo, for instance in such a way that no heterologous sequence is retained after the mutagenesis is complete. The methods employ integrative recombinant oligonucleotides (IROs). Specific examples of the described mutagenesis methods enable site-specific point mutations, deletions, and insertions. Also provided are methods that enable multiple rounds of mutation and random mutagenesis in a localized region. The described methods are applicable to any organism that has a homologous recombination system.